QUESTIONS? CALL: +90(312)4728786

Elis Ilac

Elis Ilac

Elis Ilac Company Description

T +90 (312) 472 87 86
Email: sales@elisilac.com

Elis Ilac
Ahmet Taner Kışlalı Mah. 2879. Sokak. Park Evleri Sitesi 2/2 Çayyolu-Çankaya-Ankara/TURKEY

Open in Google Maps
  • Home
  • Products
  • Our Services
  • About Us
  • Blog
  • Contact Us
ASK
  • Home
  • News
  • Drugs Approved by FDA in 2019
January 27, 2021

Drugs Approved by FDA in 2019

Drugs Approved by FDA in 2019

by arioadmin / Sunday, 27 October 2019 / Published in News

Balversa (erdafitinib); Janssen Oncology; For the treatment of locally advanced or metastatic urothelial carcinoma , Approved April 2019

Bavencio (avelumab) plus Inlyta (axitinib) ; Merck and Pfizer; For the first line treatment of advanced renal cell carcinoma, Approved May 2019

Cyramza (ramucirumab) ; Eli Lilly; For the treatment of hepatocellular carcinoma with elevated alpha-fetoprotein (AFP), Approved May 2019

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk); Halozyme; For the treatment of HER2-overexpressing breast cancer, Approved February 2019

Inrebic (fedratinib); Celgene; For the treatment of myelofibrosis, Approved August 2019

Keytruda (pembrolizumab) ; Merck; For the treatment of recurrent esophageal cancer with PD-L1 expressing tumors , Approved July 2019

Keytruda (pembrolizumab); Merck; previously treated metastatic small cell lung cancer, Approved June 2019

Keytruda (pembrolizumab); Merck; For the treatment of stage III non-small cell lung cancer, Approved April 2019

Keytruda (pembrolizumab); Merck; For the treatment of advanced renal cell carcinoma, Approved April 2019

Keytruda (pembrolizumab) plus Lenvima (lenvatinib); Merck and Eisai; For the treatment of advanced endometrial carcinoma , Approved September 2019

Nubeqa (darolutamide); Bayer; For the treatment of non-metastatic castration-resistant prostate cancer, Approved July 2019

Piqray (alpelisib) ; Novartis; For the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer, Approved May 2019

Polivy (polatuzumab vedotin-piiq) ; Genentech; For the treatment of diffuse large B-cell lymphoma, Approved June 2019

Rozlytrek (entrectinib); Genentech; For the treatment of ROS1-positive non-small cell lung cancer and NTRK Gene Fusion-Positive Solid Tumors, Approved August 2019

Tecentriq (atezolizumab); Genentech/Roche; For the treatment of extensive-stage small cell lung cancer , Approved March 2019

Tecentriq (atezolizumab); Genentech/Roche; For the treatment of triple negative breast cancer, Approved March 2019

Turalio (pexidartinib); Daiichi Sankyo; For the treatment of symptomatic tenosynovial giant cell tumor, Approved August 2019

Venclexta (venetoclax) plus Gazyva (obinutuzumab); Genentech and AbbVie; For the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma , Approved May 2019

Xpovio (selinexor) ; Karyopharm Therapeutics; For the treatment of adults with relapsed or refractory multiple myeloma , Approved July 2019

0
  • Tweet
Tagged under: markets, research

About arioadmin

What you can read next

Rare diseases: Over 300 million patients affected worldwide
Pass savings along to customers and clients with wholesale pharmaceuticals
Bed time is the best time to take blood pressure medication

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • 4% of the world’s population

    Created in 1997 by Inserm, Orphanet has progres...
  • New strategy to treat Parkinson’s disease

    Northwestern Medicine scientists have used pati...
  • Rare diseases: Over 300 million patients affected worldwide

    Rare diseases represent a global problem. Until...
  • Bed time is the best time to take blood pressure medication

    People with high blood pressure who take all th...
  • Pass savings along to customers and clients with wholesale pharmaceuticals

    Pharmaceutical wholesale products provide savin...

Recent Comments

    Archives

    • October 2019

    Categories

    • Articles
    • News
    • Scientific

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org

    Featured Posts

    • 4% of the world’s population

      0 comments
    • New strategy to treat Parkinson’s disease

      0 comments
    • Rare diseases: Over 300 million patients affected worldwide

      0 comments
    • Bed time is the best time to take blood pressure medication

      0 comments
    • Pass savings along to customers and clients with wholesale pharmaceuticals

      0 comments

    ASK FOR YOUR ORDER

    Please fill this for and we'll get back to you as soon as possible!

    FOOTER MENU

    • Home
    • Products
    • Our Services
    • About Us
    • Blog
    • Contact Us

    NEWSLETTER SIGNUP

    By subscribing to our mailing list you will always be update with the latest news from us.

    We never spam!

    GET IN TOUCH

    T +90 (312) 472 87 86
    Email: sales[at]elisilac[dot]com

    Elis Ilac
    Ahmet Taner Kışlalı Mah. 2879. Sokak. Park Evleri Sitesi 2/2 Çayyolu-Çankaya-Ankara/TURKEY

    Open in Google Maps

    • GET SOCIAL
    Elis Ilac

    © 2019 All rights reserved. Elis Ilac.

    TOP